68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease

Phase 0 Recruiting 30 enrolled First Affiliated Hospital of Chongqing Medical University

NaSingle-groupOpen-labelDiagnostic

Summary

As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA/FAP positive diseases.

Timeline

Start: 2024-05-20
Primary completion: 2025-04-30
Completion: 2026-12-31

Publications

Wang X, Zhang X, Zhang X, Guan L, Gao X, Xu L, Pang H, Du J, Zhang J, Cui M. Design, preclinical evaluation, and first-in-human PET study of [68Ga]Ga-PSFA-01: a PSMA/FAP heterobivalent tracer. Eur J Nucl Med Mol Imaging. 2025 Feb;52(3):1166-1176. doi: 10.1007/s00259-024-06965-7. Epub 2024 Nov 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	68Ga-PSFA	Diagnostic / imaging agent	—	Intravenous

Indications

No indication recorded.